Physician profile
John Fowler
NPI 1538131933
$2,481.66
in general payments reported to CMS, 2019-2025
26 companies · $433 in 2025
The $433 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $430 · 2020: $320 · 2021: $111 · 2022: $194 · 2023: $391 · 2024: $603 · 2025: $433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.38 | 2021-2025 | |
| Pfizer INC. | $471.47 | 2019-2025 | |
| Novo Nordisk INC | $461.52 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $196.30 | 2023-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $144.49 | 2020-2025 | Evenity, Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $131.73 | 2021-2025 | Breztri, Farxiga |
| Lilly USA, LLC | $55.91 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $51.55 | 2022-2023 | Myrbetriq |
| Verona Pharma, INC. | $46.46 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $42.50 | 2020 | |
| Novartis Pharmaceuticals Corporation | $37.60 | 2021 | |
| Insulet Corporation | $36.55 | 2024 | Omnipod |
| Abbott Laboratories | $35.15 | 2020-2021 | |
| Esperion Therapeutics, INC. | $32.65 | 2022 | |
| Amarin Pharma, INC. | $27.75 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $24.27 | 2024 | Voquezna |
| Edwards Lifesciences Corporation | $23.61 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sumitomo Pharma America, INC. | $23.00 | 2024 | Gemtesa |
| Xeris Pharmaceuticals, INC. | $22.66 | 2024 | Keveyis |
| Inari Medical, INC. | $20.78 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Lundbeck LLC | $19.73 | 2024 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $18.86 | 2024 | Rexulti |
| Hikma Pharmaceuticals USA | $16.11 | 2023 | Ryaltris |
| Exact Sciences Corporation | $15.28 | 2024 | Cologuard Collection Kit |
| Ars Pharmaceuticals Operations, INC. | $14.38 | 2025 | Neffy |
| Bayer Healthcare Pharmaceuticals INC. | $12.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fowler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.